200 related articles for article (PubMed ID: 25981859)
1. Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.
Studebaker A; Bondra K; Seum S; Shen C; Phelps DA; Chronowski C; Leasure J; Smith PD; Kurmasheva RT; Mo X; Fouladi M; Houghton PJ
Pediatr Blood Cancer; 2015 Oct; 62(10):1768-74. PubMed ID: 25981859
[TBL] [Abstract][Full Text] [Related]
2. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.
Bid HK; Kibler A; Phelps DA; Manap S; Xiao L; Lin J; Capper D; Oswald D; Geier B; DeWire M; Smith PD; Kurmasheva RT; Mo X; Fernandez S; Houghton PJ
Clin Cancer Res; 2013 Dec; 19(24):6716-29. PubMed ID: 24132923
[TBL] [Abstract][Full Text] [Related]
3. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
[TBL] [Abstract][Full Text] [Related]
4. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
[TBL] [Abstract][Full Text] [Related]
5. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
[TBL] [Abstract][Full Text] [Related]
6. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
Molnár E; Rittler D; Baranyi M; Grusch M; Berger W; Döme B; Tóvári J; Aigner C; Tímár J; Garay T; Hegedűs B
BMC Cancer; 2018 May; 18(1):542. PubMed ID: 29739364
[TBL] [Abstract][Full Text] [Related]
7. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
8. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
10. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for BRAFV600E malignant astrocytoma.
Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Liu D; Xing J; Trink B; Xing M
Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
[TBL] [Abstract][Full Text] [Related]
13. Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.
Balasubramanian A; Gunjur A; Gan HK; Perchyonok Y; Cher LM
J Clin Neurosci; 2020 Sep; 79():269-271. PubMed ID: 33070910
[TBL] [Abstract][Full Text] [Related]
14. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
15. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
16. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
17. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
18. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
19. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Leboeuf R; Baumgartner JE; Benezra M; Malaguarnera R; Solit D; Pratilas CA; Rosen N; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2008 Jun; 93(6):2194-201. PubMed ID: 18381570
[TBL] [Abstract][Full Text] [Related]
20. Combined BRAF
Zhang J; Yao TW; Hashizume R; Hariono S; Barkovich KJ; Fan QW; Prados M; James CD; Weiss WA; Nicolaides T
J Neurooncol; 2017 Feb; 131(3):495-505. PubMed ID: 27848137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
